{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-003553","form_type":"8-K/A","ticker":"AIXN","cik":"0000835662","company_name":"AiXin Life International, Inc.","filed_at":"2025-04-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.435260+00:00","generated_at":"2026-05-23T17:47:52.244721+00:00","sec_items":["4.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aixin Life restates 2021 results; net loss widens from $267K to $1.18M","bullets":["FY2021 net loss restated to $1,176,568 from originally reported $267,236.","Restated revenue $4,241,991 vs originally $3,066,233; operating loss $1,002,273 from $26,938.","Corrections: acquisitions of Aixin Shangyan Hotel and Aixintang Pharmacies accounted as if at start of period per ASC 805-50-45.","Also corrected capital contribution from principal shareholder Quanzhong Lin; no impact on subsequent years.","Prior auditor KCCW flagged need for restatement; company filed 8-K/A with restated financials."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-003553","json":"https://secwatch.observer/filing/0001641172-25-003553.json","markdown":"https://secwatch.observer/filing/0001641172-25-003553.md","text":"https://secwatch.observer/filing/0001641172-25-003553.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/835662/000164117225003553/0001641172-25-003553-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/835662/000164117225003553/form8-ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T17:47:52.244721+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"17b24e127efb45ec3216d4edefe5e6b1ccd62a70","claim":"AiXin Life International, Inc. reported that prior financial statements should not be relied upon.","evidence_excerpt":"(the “Company”), KCCW Certified Public Accountants (“KCCW”) advised the Company in writing of the need to restate the consolidated financial statements of the Company for the year ended December 31, 2021 (the “2021 Financial Statements”) to present the results of operations for the year ended December 31, 2021, as though the acquisitions of Aixin Shangyan Hotel Management Co., Ltd. (“Aixin Shangyan Hotel”) and Chengdu Aixintang Pharmacy Co. Ltd. and certain affiliated entities (“Aixintang Pharmacies”) had occurred at the beginning of the period. In addition to the necessary adjustments to the 2021 Financial Statements, the comparative financial statements and financial information for prior years included in the 2021 Financial Statements needed to be restated to reflect the retroactive adjustment of the financial data of previously separate entities under common control that are combined","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/835662/000164117225003553/0001641172-25-003553-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"non reliance"},{"label":"Auditor","value":"KCCW Certified Public Accountants"}],"fact_type":"auditor_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}